THE SCIENCE
Ground breaking
& inclusive
The traditional first-line treatment for psoriasis has centred on topical corticosteroids of varying potencies like hydrocortisone, which over time can lead to discolouration, skin-thinning and other side effects. These harsh treatments can also come with adverse reactions like Topical Steroid Withdrawal (TSW) when patients attempt to stop or reduce their treatment. We don't just see skin conditions - we see the person beneath, someone whose confidence and comfort have been challenged each day. This drives our relentless pursuit of revolutionary, steroid-free solutions that deliver lasting relief.
Targeting the IL-17A/SIRT1/STAT3 pathway
Granlab's innovative, steroid-free topical treatment is based on naturally derived bioactives, vitamins and minerals and targets inflammatory pathways including IL-6, TNFα, and IL-17A. Simply put, the formula works at the molecular level, where psoriasis begins. When these pathways become overactive, they trigger the rapid skin cell growth and inflammation seen in psoriasis. Our formula contains key bioactive compounds including chlorogenic acid, palmitic amide, 16-hydroxyhexadecanoic acid, and coumaric acid, which have been identified through advanced LC-QTOF analysis and demonstrated anti-inflammatory and antioxidant properties.
-
Steroid Free
GL-1, our first formulation, is a non-steroidal, oil-based, topical solution that avoids the side effects associated with traditional steroid-based treatments. It is rapidly absorbed into the skin, providing fast-acting relief for psoriasis patients. In vitro studies conducted by Centre for Applied Bioscience Research, Ireland showed our formulation matched or exceeded the performance of 1% hydrocortisone (Cortopin) across multiple parameters including safety profile, antioxidant activity, and anti-inflammatory response.
-
Gentle on all body parts
Unlike other treatments already on the market, Granlab's GL-1 formula has been tested for use on sensitive areas and can be safely applied to the most sensitive parts of the body like eyelids and genitals without risk of irritation or side effects, as confirmed through standardised OECD safety studies showing 100.98% cell viability in human tissue models. GL-1 has undergone rigorous safety testing following OECD guidelines 439, 431, and 437, demonstrating non-irritant and non-corrosive properties with over 97% cell viability in all test systems. With an estimated 1.8 million psoriasis patients in the UK experiencing inverse psoriasis, with inflamed skin occurring in sensitive areas where skin rubs together, this product could be a game-changer for those whose needs have not been met by traditional steroidal treatments
-
For all skin tones
GL-1 has also been developed to cater for the diverse needs of psoriasis patients including the 13% of patients of colour who may have had to use products and medications not developed or adequately tested for their skin tone.
